Farnesylated Protein Production via E. coli Prenylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The synthesis of proteins with compositionally defined post-translational modification (PTM) patterns, such as lipidation, remains challenging, hindering the diversification of physicochemical properties and biological behavior of proteins.
Innovation Solution
Genetically engineering E. coli to co-express desired proteins and the minimum enzymatic machinery required for prenylation, utilizing endogenously produced farnesyl pyrophosphate and prenyl transferases like farnesyltransferase and geranylgeranyl transferase-I.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional genetic code expansion methods are used to produce lipidated proteins, then protein sequence precision is maintained, but production yield is low and the method is not scalable
Solution Approach 1:
The invention divides the complex process of lipidated protein production into separate functional modules: (1) expression of the target protein with CaaX motif in E. coli, (2) endogenous biosynthesis of farnesyl pyrophosphate by E. coli metabolic pathways, and (3) post-translational farnesylation by expressed prenyl transferase enzymes. This segmentation allows each module to be optimized independently, achieving both high precision and high yield.
Solution Approach 2:
The invention utilizes the endogenous metabolic pathways of E. coli to self-produce farnesyl pyrophosphate, the lipid donor required for farnesylation. The bacterial host's native mevalonate pathway generates IPP and DMAPP, which are converted to FPP without requiring external supplementation or complex metabolic engineering, thereby simplifying the system and improving scalability.
2Manufacturing precision
If multi-step convergent semi-synthesis is used to produce lipidated proteins, then compositionally defined PTM patterns are achieved, but the process becomes laborious and technically challenging
Solution Approach 1:
The invention merges protein expression and lipidation steps into a single in vivo biosynthetic process. The target protein and prenyml transferase are co-expressed in E. coli, and farnesylation occurs co-translationally or post-translationally within the living cell, eliminating the need for separate chemical lipidation steps and significantly simplifying the overall manufacturing process.
Solution Approach 2:
The invention employs a universal CaaX motif (cysteine-any-any-hydrophobic) that can be appended to any target protein sequence to create a farnesylation substrate. This universal recognition sequence works with the expressed prenyml transferase to produce compositionally defined lipidated proteins across diverse protein targets, simplifying the approach to a single standardized protocol.
3Adaptability or versatility
If eukaryotic prenyml transferase systems are used in bacteria, then protein farnesylation capability is achieved, but system complexity increases
Solution Approach 1:
The invention extracts and expresses only the essential catalytic subunits of prenyml transferase (e.g., FTase alpha and beta subunits or GGTase-I) in E. coli, omitting complex eukaryotic regulatory proteins and membrane association domains. This minimal enzymatic machinery retains full farnesylation activity while dramatically reducing system complexity and improving bacterial expression efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the high-yield, scalable production of farnesylated proteins, allowing for the modulation of protein assembly and properties, and providing insights into the sequence-structure-function rules of lipidated proteins.
Implementation Method 1
isoprenylation is carried out by specialized transferases that bind to a lipid donor (isoprenyl pyrophosphate) and modify a recognized peptide substrate
Implementation Method 2
the modification of cysteine residues with either 15 carbon (farnesyl) or a 20 carbon (geranylgeranyl) isoprenoid lipid
Implementation Method 3
ELPs have a well-characterized lower critical solubility transition (LCST) behavior in which they undergo a soluble-to-insoluble temperature above a critical transition temperature (Tt)
Data Source
AI summary
A prokaryote was genetically engineered to develop operationally simple, high-yield biosynthetic route for the production of farnesylated proteins. The recombinant organism was modified to express a target protein, a peptide sequence fused to the target protein at a C-terminus, and an alpha and a beta subunit of a prenyltrasferase. The prenyltrasferase may be farnesyltransferase or geranylgeranyl transferase, and the peptide sequence may comprise cysteine, two hydrophobic amino acids, and an amino acid having selectivity to farnesyltransferase or geranylgeranyl transferase.